NEW YORK, June 18, 2018 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Catalyst Biosciences, Inc. (“Catalyst” or the “Company”) (NASDAQ: CBIO). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Catalyst and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On June 18, 2018, Catalyst announced that neutralizing antibodies were detected in Cohort 6 of the Phase 1/2 trial of CB 2679d/ISU304 for treatment of hemophilia B, and that Catalyst had halted the trial in order to “conduct an analysis to assess the cause and impact of the antibody observations prior to dosing any further subjects in Cohort 6.” Following this announcement, Catalyst’s share price fell sharply during intraday trading on June 18, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 9980
SOURCE Pomerantz LLP